Abstract
The traditional agents used for thromboprophylaxis are effective and safe but have limitations particularly related to ease of administration. Newer agents targeting single coagulation factors such as the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban and apixaban have demonstrated efficacy and safety for thromboembolism prophylaxis in the orthopedic population and have the additional benefit of oral administration and predictable pharmacokinetics. Pharmacology of the new anticoagulants and published data on the use of these agents in total knee and hip replacement patients will be reviewed in this article.
Keywords: Thromboprophylaxis, dabigatran, rivaroxaban, apixaban, Anticoagulants, Thromboembolism, Venous thromboembolism, low molecular, synthetic pentasaccharide, vitamin K antagonists, warfarin, narrow therapeutic index, multiple drug, DABIGATRAN ETEXILATE, quinine, verapamil, total hip replacement, total knee replacement, RE-NOVATE, creatinine, enoxaparin, nonfatal PE, proximal DVT, factor Xa, VTE prophylaxis, thrombin inhibitor, hip arthroplasty, pharmacokinetics, knee replacement
Current Pharmaceutical Design
Title: New Anticoagulants for the Prevention of Thromboembolism
Volume: 16 Issue: 31
Author(s): Kylie Lepic and Mark Crowther
Affiliation:
Keywords: Thromboprophylaxis, dabigatran, rivaroxaban, apixaban, Anticoagulants, Thromboembolism, Venous thromboembolism, low molecular, synthetic pentasaccharide, vitamin K antagonists, warfarin, narrow therapeutic index, multiple drug, DABIGATRAN ETEXILATE, quinine, verapamil, total hip replacement, total knee replacement, RE-NOVATE, creatinine, enoxaparin, nonfatal PE, proximal DVT, factor Xa, VTE prophylaxis, thrombin inhibitor, hip arthroplasty, pharmacokinetics, knee replacement
Abstract: The traditional agents used for thromboprophylaxis are effective and safe but have limitations particularly related to ease of administration. Newer agents targeting single coagulation factors such as the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban and apixaban have demonstrated efficacy and safety for thromboembolism prophylaxis in the orthopedic population and have the additional benefit of oral administration and predictable pharmacokinetics. Pharmacology of the new anticoagulants and published data on the use of these agents in total knee and hip replacement patients will be reviewed in this article.
Export Options
About this article
Cite this article as:
Lepic Kylie and Crowther Mark, New Anticoagulants for the Prevention of Thromboembolism, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563437
DOI https://dx.doi.org/10.2174/138161210793563437 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune System Modulates the Function of Adult Neural Stem Cells
Current Immunology Reviews (Discontinued) Impact of Ultrasound Contrast Agents in Echocardiographic Assessment of Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology Chronopharmaceutics: A Promising Drug Delivery Finding of the Last Two Decades
Recent Patents on Drug Delivery & Formulation Editorial [Hot Topic: Promote Healthy Eating in Women of Childbearing Age (Guest Editor: Hiroko Watanabe)]
Current Nutrition & Food Science Primary Hyperaldosteronism in the Hypertensive Disease
Current Hypertension Reviews Analysis of Nitric Oxide (NO) in Cerebral Vasospasm After Aneursymal Bleeding
Reviews on Recent Clinical Trials Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Beta-Adrenergic Antagonists: Indications and Potential Immunomodulatory Side Effects in the Critically Ill
Current Medicinal Chemistry Current Therapy of Drugs in Amyotrophic Lateral Sclerosis
Current Neuropharmacology Editorial [Hot Topic: Trends in Drug Discovery and Development (Guest Editor: Sanjay V. Malhotra)]
Current Molecular Medicine HDL-Related Mechanisms of Olive Oil Protection in Cardiovascular Disease
Current Vascular Pharmacology Antimalarial Drug Development: Past to Present Scenario
Mini-Reviews in Medicinal Chemistry Retracted: Effects of Vitamin K2 on Osteoporosis
Current Pharmaceutical Design Facilitated/Pharmaco-invasive Approaches in STEMI
Current Cardiology Reviews Efficacy of Pentoxifylline in the Management of Microalbuminuria in Patients with Diabetes
Current Diabetes Reviews Cell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design The Role of Diet in Patients with Metabolic Syndrome
Current Medicinal Chemistry Restoration of the Attenuated Neuroprotective Effect of Ischemic Postconditioning in Diabetic Mice by SGLT Inhibitor Phlorizin
Current Neurovascular Research Depression and its Relation with Uncontrolled Hypertension and Increased Cardiovascular Risk
Current Hypertension Reviews